- Home
- FRBA vs SIGA Comparison
FRBA vs SIGA Comparison
Compare FRBA & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBA | SIGA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 341.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | FRBA | SIGA |
|---|---|---|
| Price | $15.97 | $4.34 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | 71.2K | ★ 474.9K |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | 2.40% | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $6.08 | $224.81 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.41 | $4.10 |
| 52 Week High | $18.11 | $9.62 |
Technical Indicators
Market Signals| Indicator | FRBA | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 41.58 |
| Support Level | $14.71 | $4.29 |
| Resistance Level | $16.07 | $4.84 |
| Average True Range (ATR) | 0.44 | 0.16 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 75.74 | 20.83 |
Price Performance
Historical ComparisonAbout FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.